These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The numbers are in: statins for the primary prevention of cardiovascular disease in women. Duvernoy CS; Blumenthal R Circulation; 2010 Mar; 121(9):1063-5. PubMed ID: 20176993 [No Abstract] [Full Text] [Related]
4. JUPITER study highlights value of anti-inflammatory action of rosuvastatin. Cardiovasc J Afr; 2009; 20(3):211. PubMed ID: 19575096 [No Abstract] [Full Text] [Related]
5. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Ridker PM; Circulation; 2003 Nov; 108(19):2292-7. PubMed ID: 14609996 [No Abstract] [Full Text] [Related]
6. Rosuvastatin in patients with elevated C-reactive protein. Jenny-Avital ER N Engl J Med; 2009 Mar; 360(10):1039; author reply 1041-2. PubMed ID: 19271275 [No Abstract] [Full Text] [Related]
7. The editor's roundtable: the JUPITER trial--initial results and clinical implications. Ridker PM; Friedewald VE; Davidson MH; Willerson JT; Roberts WC Am J Cardiol; 2009 May; 103(10):1417-25. PubMed ID: 19427439 [No Abstract] [Full Text] [Related]
9. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention? Mora S; Ridker PM Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935 [TBL] [Abstract][Full Text] [Related]
10. The JUPITER Trial: responding to the critics. Ridker PM; Glynn RJ Am J Cardiol; 2010 Nov; 106(9):1351-6. PubMed ID: 21029837 [No Abstract] [Full Text] [Related]
11. Study stirs debate about statin use in those without high cholesterol. Mayo Clin Womens Healthsource; 2009 Apr; 13(4):3. PubMed ID: 19255535 [No Abstract] [Full Text] [Related]
12. The JUPITER trial: How will it change clinical practice? Watson KE Rev Cardiovasc Med; 2009; 10(2):91-6. PubMed ID: 19593321 [TBL] [Abstract][Full Text] [Related]
13. Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk. Stewart RA Future Cardiol; 2009 May; 5(3):231-6. PubMed ID: 19656039 [TBL] [Abstract][Full Text] [Related]
14. Rosuvastatin in patients with elevated C-reactive protein. Chan PS; Nallamothu BK; Hayward RA N Engl J Med; 2009 Mar; 360(10):1039; author reply 1041-2. PubMed ID: 19271273 [No Abstract] [Full Text] [Related]
15. [JUPITER can yield paradigmatic shift in the prevention of cardiovascular disease. Focus on inflammation as a risk factor]. Olsson AG Lakartidningen; 2009 May 20-Jun 2; 106(21-22):1471-5. PubMed ID: 19579435 [No Abstract] [Full Text] [Related]
16. Rosuvastatin in patients with elevated C-reactive protein. Pierard LA N Engl J Med; 2009 Mar; 360(10):1040; author reply 1041-2. PubMed ID: 19271277 [No Abstract] [Full Text] [Related]
17. [Comment from the family practice viewpoint]. Coradi B Praxis (Bern 1994); 2009 Feb; 98(3):131. PubMed ID: 19180439 [No Abstract] [Full Text] [Related]
18. Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk. Nicholls SJ; Uno K; Kataoka Y Expert Rev Cardiovasc Ther; 2011 Nov; 9(11):1383-90. PubMed ID: 22059787 [TBL] [Abstract][Full Text] [Related]
19. Public health. U.S. panel favors wider use of preventive drug treatment. Couzin-Frankel J Science; 2010 Jan; 327(5962):130-1. PubMed ID: 20056859 [No Abstract] [Full Text] [Related]
20. JUPITER, rosuvastatin, and the European Medicines Agency. Ridker PM; Glynn RJ Lancet; 2010 Jun; 375(9731):2071. PubMed ID: 20494436 [No Abstract] [Full Text] [Related] [Next] [New Search]